OncoAlert
@OncoAlert
Followers
39K
Following
119K
Media
4K
Statuses
107K
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨
Worldwide
Joined March 2019
The OncoAlert🚨Newsletter Now Out !! .Covering June 23-July 3, 2025 . REGISTER at OR Discussing:.✅Update on FORTITUDE-101 (Industry) GEJ.✅ShortHER in #BreastCancer.✅U-BOMB Trial in Breast #Cancer.✅DADSPORT in
0
6
21
RT @JournalCancer: ICYMI: A new joint series w/ @AnnSurgOncol is now available, focusing on consensus guidelines for managing peritoneal su….
0
7
0
RT @VJOncology: NEW #VJOncoAlert Journal Club episode from.@VJOncology and @OncoAlert🚨. Ali Shamseddine goes through the Averectal study of….
0
2
0
RT @Lucarecco: Published in @BrJCancer: primary breast cancer resection in metastatic pts did not improve OS (median 75 vs 69m) but signifi….
0
5
0
RT @nataliagandur: 🧬 First-in-human study of [¹⁶¹Tb]Tb-PSMA-I&T in mCRPC (VIOLET trial).📌 Published in The Lancet Oncology.@thelancet @Onco….
0
6
0
RT @nataliagandur: 🌟🧬 Universal Germline + Tumor Testing: The Real Diagnosis🌟.@Dr_R_Kurzok @VivekSubbiah @JCOOA_ASCO @ASCO @OncoAlert.🔥 Pow….
0
11
0
RT @OscarTahuahua: Immune Checkpoint Inhibitor‐Based Therapy as the First‐Line Treatment for Advanced NSCLC. Efficacy, challenges & futur….
0
59
0
RT @CACancerJournal: A recent study found that patients with oral mucositis, dry mouth, gingival sensitivity, and gingival pain had a signi….
0
1
0
RT @DarcyBurbage: Great infographic from the inaugural #ESCardioOnco2025 @escardio on atherosclerosis associated w/#ICI .@OncoAlert @PallOn….
0
3
0
RT @MarioBalsaMD: 👀 Ph2 MoST-CIRCUIT: Nivo+Ipi in advanced gynecological clear cell cancers (n=28 | 17 sites in Australia & New Zealand).ht….
0
4
0
RT @AndreaNecchi: Understanding the Utility of Circulating Tumor DNA for Bladder Preservation in Patients With Muscle-Invasive Bladder Canc….
0
7
0
RT @Lucarecco: For pts with HR+/HER2-, stage III, eBC, how do you choose between #abemaciclib and #ribociclib in the adjuvant setting? Does….
0
6
0
Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial . . In a randomized study of 407 patients with de novo stage IV #BreastCancer , primary tumor
1
16
24
RT @OncoAlert: News From Industry.Source: AstraZeneca. The European Commission has approved AstraZeneca’s Imfinzi (durvalumab) as the first….
0
17
0
RT @nataliagandur: 💫🌟🔬 Facts and Hopes in Radioimmunotherapy of Oligometastatic Disease🌟💫.by @DrHuangDQ @SeanPitroda @rweichselbaum.📌 @CCR_….
0
13
0
RT @Erman_Akkus: 📘Future medical management of pancreatic cancer.@myESMO . ✅New targets, strategies, personalization. 👉.
0
17
0
RT @APCCC_Lugano: First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic….
0
10
0
RT @mirrorsmed: Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER+/HER2- breast cancer. https….
0
5
0
RT @to_be_elizabeth: 📌 Impact of Ethnicity on Breast Cancer Outcome: A Systematic Review and Meta-Analysis of Randomized Phase III Trials o….
0
2
0
RT @MarioBalsaMD: 📢 ¡A must-read for residents!. A timely review in @FrontImmunol dives into antibody-based strategies for #HCC. https://t….
0
7
0